Agilent Technologies, Inc. (NYSE:A) Q1 2024 Earnings Conference Call February 27, 2024 4:30 PM ET
Company Participants
Parmeet Ahuja - Investor Relations
Padraig McDonnell - Chief Operating Officer & Chief Executive Officer-elect
Mike McMullen - President & Chief Executive Officer
Robert McMahon - Senior Vice President & Chief Financial Officer
Angelica Riemann - President of Agilent CrossLab Group
Phil Binns - President of Agilent Life Sciences & Applied Markets Group
Conference Call Participants
Derik De Bruin - Bank of America
Matt Sykes - Goldman Sachs
Brandon Couillard - Jefferies
Puneet Souda - Leerink Partners
Rachel Vatnsdal - JPMorgan
Patrick Donnelly - Citigroup Inc.
Daniel Brennan - TD Cowen
Catherine Schulte - Baird
Jack Meehan - Nephron Research
Doug Schenkel - Wolfe Research
Josh Waldman - Cleveland Research
Dan Leonard - UBS
Luke Sergott - Barclays
Paul Knight - KeyBanc
Operator
Ladies and gentlemen, welcome to the Agilent Technologies Q1 2024 Earnings Call. My name is Regina and I will be coordinating your call today. [Operator Instructions]
I will now hand you over to your host, Parmeet Ahuja, to begin. Please go ahead.
Parmeet Ahuja
Thank you, Regina and welcome, everyone, to Agilent's conference call for the first quarter of fiscal year 2024. With me are Mike McMullen, Agilent's President and CEO; Padraig McDonnell, Agilent Chief Operating Officer and CEO-elect; and Bob McMahon, Agilent's Senior Vice President and CFO and acting President of the Diagnostics and Genomics Group. Joining in the Q&A will be Phil Binns, President of the Agilent Life Science and Applied Markets Group; and Angelica Riemann, our newly named President of the Agilent CrossLab Group. This presentation is being webcast live. The news release for our first quarter financial results, investor presentation and information to supplement today's discussion along with the recording of this webcast are available on our website at www.investor.agilent.com.
Today's comments will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year and references to revenue growth are on a core basis. Core revenue growth excludes the impact of currency and any acquisitions and divestitures completed within the past 12 months. Guidance is based on forecasted exchange rates. As previously announced, beginning in the first quarter of fiscal 2024, we implemented certain changes to our segment reporting structure related to the move of our cell analysis business from LSAG into DGG. We have recast our historical segment information to reflect these changes. These changes have no impact on our company's consolidated financial statements.